Background: In this era of comparative effectiveness research, new, advanced techniques are being investigated by the research community to overcome the limitations of existing data sources. We describe the approach of probabilistic data linkage as a means to address this critical issue.
Introduction
The ability to compare the relative effectiveness of different technologies and treatment modalities is now imperative in order to meet the growing demand for more rigorous outcomes research. Today, there are many data available to conduct comparative effectiveness research (CER) [1] : 1) data from surveys and 2) data from secondary databases; however, many lack important information. Both of these types of data sources have their own particular limitations. While prospectively collected observational cohorts lend themselves to longitudinal epidemiologic data for research, they are traditionally limited in external validity, specificity of measurement on key exposures and outcomes, and historially dated beyond application to current therapies. Secondary databases, including administrative claims data collected by the infrastructure of the healthcare system for the purposes of payment for services, also have limitations, as they are typically restricted to billing claims and provide limited clinical detail to confirm disease. Additionally, they often contain few patient characteristics (such as race and ethnicity) and have a low proportion of indigent and self-pay populations. These types of databases also lack in details on patients' perception of disease or the impact of disease or treatment on humanistic outcomes. Electronic medical record (EMR) systems, newly launched to replace paper-based chart systems in tracking clinical symptoms and disease, are still in the early stages of development. Moreover, they are frequently positioned in silos of healthcare practice -traditionally physician practices with limited linkage to inpatient facilities, other specialists or other physician services, emergency and acute services, and pharmacy services.
While each of these datasets provides unique information, they lack a significant amount of information about the patients themselves and their associated treatments. Given these challenges and data limitations, there is a need for new, advanced techniques to overcome the limitations of existing data sources, thereby enhancing their utility for CER. Herein we describe the approach of probabilistic data linkage in addressing this critical issue.
Overview of data linkage
In the absence of the ideal data source, there is an alternative: a method whereby researchers can maximize the benefits of each individual type of data source, utilizing data linkage methods to fill in the gaps of one database with the strengths of another. Blanchette et al. presented this approach at a workshop during the 13 th Annual European ISPOR Congress in Prague in 2010 [2] , and discussed preliminary results demonstrating the application linking the two administrative databases, at a workshop during the 16 th Annual International ISPOR meeting in Baltimore, in 2011 [3] .
Database linkage methods generally employ both deterministic and probabilistic linking algorithms [4, 5, 6] . Deterministic linkage techniques can be applied when both datasets provide patient-identifying information that can be cross-matched between the two datasets. This is the preferred form of data linkage because the focus is on matching the same patient from both datasets. In the current climate of regulatory and legal restraints on the use of personal health information (PHI), the utility of this approach is limited. In the absence of PHI, a probabilistic method may be applied. However, the focus is not on identifying the same patient but rather on two matching patients with similar behavior and characteristics [7, 8, 9] . The goal of both of these efforts is to identify the best method for pair-matching between datasets.
Probabilistic linking methods incorporate varying strengths of identifiers, depending on information provided by the identifier. Stronger weights are given to matches for identifiers upon which matching is less likely. For example, matching on gender (male or female) is less likely to produce a matching of equivalent records than matching a record on the combination of birth month and year. Assigned weights are related to frequencies of occurrences of values in linked and unlinked pairs and also to the designated level of agreement [10] . The determination of agreement can be further defined into subcategories: agreement (yes/ no) or varying levels of partial agreement (e.g., matching of a date within 2 days before/after or matching within a week before/ after). Using probabilistic linking methods generally increases the sensitivity and specificity of models over a deterministic method in linking records from disparate datasets.
Propensity score methods are increasingly used to match similar individuals in observational studies, along with other approaches to control for channeling bias [11, 12] . These methods are similar to the approach used in probabilistic data linkage.
In propensity score matching, well-matched pairs are closely matched on the predicted probability of experiencing the dependent variable using relevant covariates. Matching techniques then employ a variety of approaches based on the predicted probability score (ranging from 0 to 1), including nearest neighbor matching heuristics, and often employing sampling without replacement [13, 14] .
Methodology
To demonstrate the utility and subsequent validity of probabilistic data linkage we employed a historical retrospective cohort design. Patients aged 40 and older with a principal or secondary diagnosis of COPD (International Classification of Disease, 9 th Revision codes: 491.xx, 492.xx, and 496) and at least 3 years of continuous enrollment in a US health plan contributing to the database between January 1, 2004 and April 30, 2009 were selected from two administrative claims databases representing commercially insured US health plan enrollees. The index date was designated as the date of the first claim (defined by a 12-month wash-out pre-index period) for either study drug, Treatment 1 or Treatment 2. The effectiveness measure was the incidence of COPD-related exacerbation (hospitalization, emergency department visit or oral corticosteroid prescription) observed in the 12-month post-index period, with baseline characteristics being identified in the 12-month pre-index period (Figure 1) .
Data linkage was performed by restricting the samples in each database to those with similar pre-index and post-index time periods (as described above). We then pooled data and developed a logistic regression model predicting the propensity to be in Database A using overlapping pre-index variables including age, geographic region, comorbidities, and pre-index utilization of health services and respiratory medications (Table 1) . Patients from both databases were matched on the propensity score. We then directly imputed the outcomes of each matched patient from Database A to the matched patient from Database B. Finally, we conducted the comparative effectiveness study in each cohort (A, B, and A with imputed outcomes) (Figure 2 ). Table 2 ). This is not entirely surprising since the probability of being in each cohort was determined by the overlapping similarity in characteristics between the two cohorts, just as if the propensity score match was used in a traditional cohort analysis.
Discussion
The probabilistic linkage demonstrated that patients from different databases matched on similar pre-index characteristics may demonstrate similar outcomes in the post-index period. The implication of these findings and this approach is significant as it provides a case example for linkage of simulated cohorts from varying databases (e.g., EMR and administrative datasets, administrative datasets and surveys, EMR and surveys, etc.).
The creation of simulated cohorts could help explain a more complete picture of patient outcomes and allow researchers to explore all aspects of a patient experience -economic, clinical, and humanistic through the use of retrospective data analysis. For example, the use of administrative claims databases for comparative effectiveness research is often lacking key variables of interest such as income, race, lab results, clinical detail identified through notes, etc. Through this linking technique, one could impute these characteristics into a similar matched-patient cohort and assess the associations with the outcome. Similarly, a survey of patients could be augmented with key administrative and clinical detail. Even a clinical trial sample could be matched to administrative or electronic health record data to populate long-term outcomes. This technique has the ability to provide a view into the world of more complete data with further validation of the methods and use in diverse data sources. There are several limitations worth noting related to this type of data linkage. The divergence of the measures between the databases may also cause a divergence in "like" patients thereby introducing error in the outcomes assessment. Care should be taken to ensure that similar measures are used to build the logistic regression model to create the propensity score; the assumption is that probabilistic matching produces two individuals with similar attributes and not the same individual. However, in the absence of complete data, the approach offers a good start and paves the way for further examples of this type of linkage method to be explored with various databases.
These data represent US-based administrative claims submitted from healthcare providers to health insurance plans and therefore there is a potential for miscoded claims. It is assumed that these patients fully utilize their health insurance benefits to avoid the full cost of the health service; however unlikely, there is a potential that the patient may be receiving health benefits from a provider who does not submit a claim for reimbursement to the patient's health insurance provider.
Conclusions
The probabilistic linkage method for simulated cohorts demonstrated that patients from different US-based health plan administrative claims databases matched on similar pre-index characteristics may demonstrate similar outcomes in the post-index period. This is the first application of this method for comparative effectiveness research and further validation in diverse datasets is required.
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